Health-related quality of life during a phase 2 study of talazoparib in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO).
Authors
Hurvitz, STurner, N
Telli, M
Rugo, H
Mailliez, A
Ettl, J
Grischke, E
Mina, L
Balmaña, J
Fasching, P
Tudor, C
Quek, R
Hannah, A
Robson, M
Wardley, Andrew M
Affiliation
Cancer Research University of California Los Angeles Health, Santa Monica, CAIssue Date
2018-02-14
Metadata
Show full item recordCitation
Health-related quality of life during a phase 2 study of talazoparib in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). 2018, 78(4 Suppl): P5-19-05 Cancer ResJournal
Cancer ResearchDOI
10.1158/1538-7445.SABCS17-P5-19-05Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.SABCS17-P5-19-05